August 2018 On behalf of the members, BioMelbourne Network has made a submission to Treasury regarding the proposed changes to the R&D Tax Incentive. In terms of our overall consideration of the proposed changes to the R&D Tax…
Read MoreMay 2018 The biotechnology, medical technology and pharmaceutical sector in Victoria is vibrant and growing but yet to reach its full potential contribution to the Victorian economy. Historical support from governments has allowed the sector to grow, now…
Read MoreOctober 2017 “Australia’s visa system must remain globally competitive to attract talent to build future industries and transition to a knowledge-led economy” Health is a global market and access to global talent is critical for healthcare innovation. Companies…
Read MoreSeptember 2017 Continued Discussions : Pharmaceutical Manufacturing: Driving Competitive Advantage for Victoria BioMelbourne Network convened a roundtable with Minister Wade Noonan, Minister Philip Dalidakis and 14 pharmaceutical and biotechnology companies who currently manufacture or develop products for manufacture…
Read MoreJuly 2017 Restoration on skilled visas welcomed across medical technology, biotechnology and pharmaceutical sector. The restoration of key occupations for the medical technology, research and pharmaceutical sector to the skilled migration visa list has been welcomed by six…
Read MoreJuly 2017 Revisions to the skilled migration list have been welcomed by many BioMelbourne Network members across the biotechnology, medical technology and pharmaceutical sector. The restoration of occupations such as life scientist, biotechnologist, CEO/General Manager, and biochemist to…
Read MoreBioMelbourne Network CEO, Dr Krystal Evans attended a technology industries roundtable discussion with the Department of Immigration and the Department of Industry regarding skilled migration and the decision to abolish the 457 visa program. The medical technology, biotechnology and…
Read More18 April 2017 Don’t rip the guts out of Australian medical research commercialisation Commercialisation of Australian medical research is under serious threat if the package of measures put by the ‘Ferris, Finkel, Fraser’ Review of the Research &…
Read MoreSeptember 2016 The R&D Tax Incentive Review paper was released on 28th of September, making recommendations on changes to the scheme – including a proposed $2Million cap on the annual cash refund payable under the R&D Tax Incentive.…
Read MoreSeptember 2015 The Committee for Melbourne has announced the members of the MELBOURNE 4.0 Steering Committee. The Steering Committee will drive the MELBOURNE 4.0 engagement process and ensure concrete policy initiatives are identified. Reflective of the Committee for…
Read MoreSeptember 2016 A new pathway for engagement with the Federal Government on issues concerning the sector is through the recently established Industry Growth Centres. Last week, BioMelbourne Network held a CEO lunch with Sue MacLeman, CEO MTPConnect as…
Read MoreAugust 2016 Leadership | Culture | Communication | Collaboration | Human Capital | Scale These were the strong themes emerging from the Nature 2016 Research Translation and Innovation Symposium held in Canberra last week on Thursday 11th of…
Read More